Since 2000, LRAAC has conducted research on new treatments for allergies, asthma, urticaria, influenza, hereditary angioedema and COPD. In our 22 years we have completed over 170 clinical trials. Research related care is provided at no cost and compensation may be available for time/travel. If you would like to hear more about current clinical trials at LRAAC, call Mindy DeMarco RN,BSN,CCRP at 501-224-1156 Option 7.
Novartis Pharmaceuticals trial entitled: A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064)to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately
controlled by H1-antihistamines.
CSL312_3002, An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema.
Novartis Pharmaceuticals trial entitled: A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolescents and adults inadequately controlled with H1-antihistamines.
A Phase II, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants with Uncontrolled Moderate-to-severe Asthma. (FRONTIER-3).